As of Nov 19, 2026, 2 of 2 active firms rate CLRB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CLRB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.52
Range $-0.53 – $-0.50 · 2 analysts · -61% YoY
Next period, 2 analysts expect Cellectar Biosciences Inc to earn $-0.52 a share (range $-0.53 – $-0.50), versus $-1.33 a year earlier. Full-year consensus is $-2.25, growing to $-2.03 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Cellectar Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CLRB.
#1
Jeff Jones
Oppenheimer · Rank #320
Neutral
No targeton CLRB
Overall win rate
32%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #567
Buy
$10.00+1036.0% to target
Overall win rate
30%
+ Follow
#3
Jonathan Aschoff
Roth MKM · Rank #588
Buy
$11.00+1149.6% to target
Overall win rate
28%
+ Follow
#4
KD
Kevin DeGeeter
Ladenburg Thalmann
Buy
$10.00+1036.0% to target
Coverage
—
+ Follow
#5
KD
Kemp Dolliver
Brookline Capital Markets
Buy
$15.00+1604.0% to target
Coverage
—
+ Follow
CLRB stock forecast FAQ
What is CLRB's average 12-month price target?+
The 2 active firms with a live target average $10.00 for Cellectar Biosciences Inc over the next 12 months, ranging from a $10.00 high to a $10.00 low, as of Nov 19, 2026.
Is CLRB stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover CLRB?+
2 active firms have a recognized rating on Cellectar Biosciences Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CLRB?+
Among analysts who currently cover CLRB, Jeff Jones of Oppenheimer has the strongest overall Quantellect track record (Rank #320). Their current call is Neutral.
What is Cellectar Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.52 per share (range $-0.53 – $-0.50) across 2 analysts. Full-year EPS is projected at $-2.25, rising to $-2.03 the following year.
How much revenue is Cellectar Biosciences Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading CLRB lately?+
As of Nov 19, 2026, 2 of 2 active firms rate CLRB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CLRB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.